Copyright Reports & Markets. All rights reserved.

Global Anti-VEGF Drugs for the Treatment of Wet AMD Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Single target Drugs
    • 1.3.3 Multi-target Drugs
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Other
  • 1.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size & Forecast
    • 1.5.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity (2021-2032)
    • 1.5.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product and Services
    • 2.1.4 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments/Updates
  • 2.2 Novartis
    • 2.2.1 Novartis Details
    • 2.2.2 Novartis Major Business
    • 2.2.3 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product and Services
    • 2.2.4 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novartis Recent Developments/Updates
  • 2.3 Coherus BioSciences
    • 2.3.1 Coherus BioSciences Details
    • 2.3.2 Coherus BioSciences Major Business
    • 2.3.3 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product and Services
    • 2.3.4 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Coherus BioSciences Recent Developments/Updates
  • 2.4 Regeneron Pharmaceuticals
    • 2.4.1 Regeneron Pharmaceuticals Details
    • 2.4.2 Regeneron Pharmaceuticals Major Business
    • 2.4.3 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product and Services
    • 2.4.4 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Regeneron Pharmaceuticals Recent Developments/Updates
  • 2.5 Samsung Bioepis
    • 2.5.1 Samsung Bioepis Details
    • 2.5.2 Samsung Bioepis Major Business
    • 2.5.3 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product and Services
    • 2.5.4 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Samsung Bioepis Recent Developments/Updates
  • 2.6 Biocon Biologics
    • 2.6.1 Biocon Biologics Details
    • 2.6.2 Biocon Biologics Major Business
    • 2.6.3 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product and Services
    • 2.6.4 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Biocon Biologics Recent Developments/Updates
  • 2.7 Chengdu Kanghong Pharmaceutical
    • 2.7.1 Chengdu Kanghong Pharmaceutical Details
    • 2.7.2 Chengdu Kanghong Pharmaceutical Major Business
    • 2.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Drugs for the Treatment of Wet AMD Product and Services
    • 2.7.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Anti-VEGF Drugs for the Treatment of Wet AMD by Manufacturer

  • 3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Manufacturer (2021-2026)
  • 3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Anti-VEGF Drugs for the Treatment of Wet AMD by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturer Market Share in 2025
  • 3.5 Anti-VEGF Drugs for the Treatment of Wet AMD Market: Overall Company Footprint Analysis
    • 3.5.1 Anti-VEGF Drugs for the Treatment of Wet AMD Market: Region Footprint
    • 3.5.2 Anti-VEGF Drugs for the Treatment of Wet AMD Market: Company Product Type Footprint
    • 3.5.3 Anti-VEGF Drugs for the Treatment of Wet AMD Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Region
    • 4.1.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Region (2021-2032)
    • 4.1.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price by Region (2021-2032)
  • 4.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value (2021-2032)
  • 4.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value (2021-2032)
  • 4.5 South America Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Type (2021-2032)
  • 5.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Type (2021-2032)
  • 5.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Application (2021-2032)
  • 6.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Application (2021-2032)
  • 6.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Type (2021-2032)
  • 7.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Application (2021-2032)
  • 7.3 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
    • 7.3.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Type (2021-2032)
  • 8.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Application (2021-2032)
  • 8.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
    • 8.3.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Region
    • 9.3.1 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Type (2021-2032)
  • 10.2 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Application (2021-2032)
  • 10.3 South America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
    • 10.3.1 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
    • 11.3.1 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Anti-VEGF Drugs for the Treatment of Wet AMD Market Drivers
  • 12.2 Anti-VEGF Drugs for the Treatment of Wet AMD Market Restraints
  • 12.3 Anti-VEGF Drugs for the Treatment of Wet AMD Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Anti-VEGF Drugs for the Treatment of Wet AMD and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Anti-VEGF Drugs for the Treatment of Wet AMD
  • 13.3 Anti-VEGF Drugs for the Treatment of Wet AMD Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Anti-VEGF Drugs for the Treatment of Wet AMD Typical Distributors
  • 14.3 Anti-VEGF Drugs for the Treatment of Wet AMD Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Anti-VEGF Drugs for the Treatment of Wet AMD market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Anti-VEGF drugs play a critical role in the treatment of wet age-related macular degeneration(AMD),a leading cause of severe vision loss in older adults.Drugs such as ranibizumab(Lucentis),aflibercept(Eylea),and brolucizumab(Beovu)are specifically designed to inhibit vascular endothelial growth actor(VEGF).By blocking VEGF,these medications help to reduce the formation of new vessels,decrease fluid leakage into the retina,and stabilize or improve vision in patients with wet AMD.
    This report is a detailed and comprehensive analysis for global Anti-VEGF Drugs for the Treatment of Wet AMD market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Anti-VEGF Drugs for the Treatment of Wet AMD market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Anti-VEGF Drugs for the Treatment of Wet AMD market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Anti-VEGF Drugs for the Treatment of Wet AMD market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Anti-VEGF Drugs for the Treatment of Wet AMD market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Anti-VEGF Drugs for the Treatment of Wet AMD
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Anti-VEGF Drugs for the Treatment of Wet AMD market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Chengdu Kanghong Pharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Anti-VEGF Drugs for the Treatment of Wet AMD market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Single target Drugs
    Multi-target Drugs
    Market segment by Application
    Hospital and Clinic
    Retail Pharmacies
    Other
    Major players covered
    Roche
    Novartis
    Coherus BioSciences
    Regeneron Pharmaceuticals
    Samsung Bioepis
    Biocon Biologics
    Chengdu Kanghong Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Anti-VEGF Drugs for the Treatment of Wet AMD product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD, with price, sales quantity, revenue, and global market share of Anti-VEGF Drugs for the Treatment of Wet AMD from 2021 to 2026.
    Chapter 3, the Anti-VEGF Drugs for the Treatment of Wet AMD competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Anti-VEGF Drugs for the Treatment of Wet AMD breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Anti-VEGF Drugs for the Treatment of Wet AMD market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGF Drugs for the Treatment of Wet AMD.
    Chapter 14 and 15, to describe Anti-VEGF Drugs for the Treatment of Wet AMD sales channel, distributors, customers, research findings and conclusion.

    Buy now